Core Viewpoint - Weigao Co., Ltd. has been actively repurchasing its shares, indicating a strategy to support its stock price amid recent declines [2][3]. Share Buyback Activity - On November 10, Weigao repurchased 682,000 shares at a price range of HKD 5.300 to HKD 5.420, totaling HKD 3.6511 million [2]. - The stock closed at HKD 5.370 on the same day, reflecting a decrease of 0.92%, with a total trading volume of HKD 152 million [2]. - Since November 6, the company has conducted buybacks for three consecutive days, acquiring a total of 1.2176 million shares for a cumulative amount of HKD 6.5485 million, during which the stock price fell by 1.65% [2]. Year-to-Date Buyback Summary - Year-to-date, Weigao has executed 76 buybacks, acquiring a total of 23.8008 million shares for a total expenditure of HKD 133 million [3]. - The detailed buyback data shows various dates, share quantities, and price ranges, indicating a consistent buyback strategy throughout the year [3][4][5].

Core Viewpoint - Weigao International Holding Corporation Pte. Ltd. has entered into a joint venture agreement with PT Oneject Indonesia to establish Oneject Wego Medical in Indonesia, focusing on local production of medical consumables [1][2] Group 1: Joint Venture Details - The joint venture will be owned 45% by Weigao International and 55% by the joint venture partner [1] - The joint venture will manufacture and sell intravenous catheters, infusion sets, and other medical consumables, targeting products that are currently heavily imported into Indonesia [1] - The partner, PT Oneject Indonesia, is a subsidiary of GDK Company, a leading manufacturing and sales group in Indonesia, which will provide extensive resources and market knowledge [1] Group 2: Strategic Benefits - The establishment of the joint venture is expected to allow the company to enter emerging overseas markets, expand its customer base, and create synergies with existing operations [2] - The board believes that the joint venture aligns with the overall interests of the company and its shareholders [2]

Core Viewpoint - Weigao International Holding Corporation Pte. Ltd. has entered into a joint venture agreement with PT Oneject Indonesia to establish Oneject Wego Medical in Indonesia, aiming to manufacture and sell medical consumables locally, reducing reliance on imports [1][2] Group 1: Joint Venture Details - The joint venture will be owned 45% by Weigao International and 55% by the joint venture partner [1] - The joint venture will not consolidate its financial performance into the company's accounts [1] - The business activities will focus on manufacturing and selling intravenous catheters, infusion sets, and other medical consumables in Indonesia [1] Group 2: Strategic Rationale - The establishment of the joint venture is expected to allow the company to enter emerging overseas markets and expand its customer base [2] - The joint venture is anticipated to create synergies with the company's existing operations [2] - The board believes that the joint venture aligns with the overall interests of the company and its shareholders [2] Group 3: Partner Profile - The joint venture partner is a subsidiary of GDK Company, a leading manufacturing and sales group in Indonesia [1] - The partner specializes in producing standard syringes, safety and smart auto-disable syringes, blood bags, dialysis products, and blood collection tubes [1] - The partner's established resources, network, and market knowledge will help identify suitable opportunities in the Indonesian market [1]

董事会认为，成立合营企业将使集团得以进军新兴海外市场、扩大客户群并与集团的现有业务产生协同 效益。监 合营企业的业务活动包括在印尼制造及销售静脉留置针、输液器及其他医疗耗材，其将继续专注于本地 化生产，目标产品为印尼目前高度依赖进口的产品。 合营伙伴为一家于印尼注册成立的公司，为GDK Company(一家集制造及销售业务于一体的印尼领先企 业集团)之附属公司。合营伙伴主要生产标准注射器、安全与智能自动禁用式注射器、血袋、血液透析 及采血管。作为印尼的领先制造商之一，合营伙伴可令合营企业利用其广泛资源、成熟网络及深厚市场 知识物色印尼市场的合适商机。 格隆汇11月10日丨威高股份(01066.HK)宣布，于2025年11月6日，公司全资附属公司Weigao International Holding Corporation Pte. Ltd.("威高国际控股")与PTOneject Indonesia("合营伙伴")就于印尼成立合营企业 Oneject Wego Medica订立合营协议。合营企业将由威高国际控股持有45%权益及由合营伙伴持有55%权 益。合营企业将入账列作公司之合营企业及其财务业绩将不会综合 ...

Core Viewpoint - Weigao Group (01066.HK) announced a share buyback on November 10, spending HKD 3.6511 million to repurchase 682,000 shares at a price range of HKD 5.30 to HKD 5.42 per share [1] Summary by Category Company Actions - The company executed a buyback of 682,000 shares, indicating a commitment to enhancing shareholder value [1] - The total expenditure for the buyback was HKD 3.6511 million, reflecting the company's financial strategy [1] Share Price Information - The repurchase price per share ranged from HKD 5.30 to HKD 5.42, which may suggest the company's valuation perspective on its own shares [1]

Group 1 - The company, Weigao Group (01066), announced a share buyback on November 10, 2025, spending HKD 3.65114 million to repurchase 682,000 shares [1]

Core Viewpoint - Weigao Group (01066) announced a share buyback of 682,000 shares at a cost of HKD 3.65114 million on November 10, 2025 [1] Summary by Category - **Company Actions** - The company executed a share repurchase, indicating a commitment to returning value to shareholders [1] - **Financial Details** - The total expenditure for the buyback was HKD 3.65114 million, which reflects the company's financial strategy and market confidence [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2025年11月10日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01066 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 山東威高集團醫用高分子製品股份有限公 司 Shandong Weigao Group Medical Polymer Company Limited * （在中華人民共和國註冊成立的股份有限公司） （股份代號：1066） 自願性公告 成立合營企業 本公告乃由山東威高集團醫用高分子製品股份有限公司（「本公司」，連同其附 屬公司統稱「本集團」）自願發出。 本公司董事會（「董事會」）謹此宣佈，於2025年11月6日，本公司全資附屬公 司Weigao International Holding Corporation Pte. Ltd.（「威高國際控股」）與PT Oneject Indonesia（「合營夥伴」）就於印尼成立合營企業Oneject Wego Medical （「合營企業」）訂立合營協議。合營企業將由威高國際控股持有45%權益及由 合營夥伴持有55%權益。合營企業將入賬列作本公司之合營企業及其財 ...

Group 1 - The company, Weigao Group (01066.HK), announced a share buyback on November 7, spending HKD 1.0605 million to repurchase 195,600 shares at a price range of HKD 5.40 to 5.44 per share [1] - On November 6, the company also conducted a buyback, spending HKD 1.8368 million to repurchase 340,000 shares [1]